Allergy immunotherapy sublingual - Stallergenes Greer plc

Drug Profile

Allergy immunotherapy sublingual - Stallergenes Greer plc

Alternative Names: Staloral; STALORAL 300 IR; Staloral Grass 300; Staloral Mites 300

Latest Information Update: 29 Aug 2016

Price : $50

At a glance

  • Originator Stallergenes SA
  • Developer Stallergenes Greer plc
  • Class Allergy immunotherapies; Antiallergics
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Allergic asthma; Allergic rhinitis

Most Recent Events

  • 29 Aug 2016 No recent reports on development identified - Phase-III for Allergic asthma in China (Sublingual)
  • 01 Oct 2013 Launched for Allergic asthma in Australia (Sublingual)
  • 01 Oct 2013 Launched for Allergic rhinitis in Australia (Sublingual)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top